Summary:
- The global onychomycosis treatment market size reached USD 3.5 Billion in 2023.
- The market is expected to reach USD 5.2 Billion by 2032, exhibiting a growth rate (CAGR) of 4.6% during 2024-2032.
- North America leads the market, accounting for the largest onychomycosis treatment market share.
- Distal subungual onychomycosis accounts for the majority of the market share in the disease type segment as distal subungual onychomycosis is the most prevalent form of nail fungus, contributing significantly to overall cases and driving demand for targeted treatment options.
- Drug treatment holds the largest share in the onychomycosis treatment industry.
- Based on the drug class, the market has been categorized into allylamine, azole, griseofulvin, and others.
- Retail pharmacies remains a dominant segment in the market, as the primary point of access for patients seeking over-the-counter and prescription treatments, facilitating convenience and accessibility.
- The increasing incidences of skin conditions are a primary driver of the onychomycosis treatment market.
- The onychomycosis treatment market growth and forecast highlight a significant rise due to the significant expansion of e-commerce and growing healthcare expenditure.
Industry Trends and Drivers:
- Increased Incidence of Skin Conditions:
The rising prevalence of skin conditions, including psoriasis and eczema, which are often associated with onychomycosis, is a significant factor fueling market growth for antifungal treatments. Additionally, psoriasis and eczema can weaken skin and nail barriers, making individuals more susceptible to fungal infections like onychomycosis, which is driving the onychomycosis treatment market size. Moreover, due to this link, patients experiencing chronic skin issues are actively seeking targeted treatments to manage their condition, which further intensifies the demand for antifungal products. Besides, as awareness around these skin conditions grows, people are more likely to recognize the signs of secondary infections, leading them to pursue medical intervention. Furthermore, the easy availability of resources and information about skin health encourages a proactive approach to treatment, creating a more engaged consumer base.
- E-commerce Expansion:
The onychomycosis treatment market trends indicate that the rapid expansion of e-commerce platforms has revolutionized access to antifungal treatments, playing a crucial role in the growth of the onychomycosis treatment market. Additionally, with online shopping becoming an integral part of consumer behavior, patients now have the convenience of purchasing over-the-counter (OTC) and prescription antifungal medications from the comfort of their homes. This shift has greatly enhanced accessibility, especially for individuals in remote or underserved areas who may lack nearby pharmacies or healthcare facilities. Moreover, e-commerce platforms also offer an extensive range of products, enabling customers to compare various brands and read reviews, which empowers informed decision-making. Furthermore, several online retailers offer discrete shipping, which is appealing to those who may feel uncomfortable purchasing antifungal products in person. As digital retail continues to grow, e-commerce will likely remain a key driver of market penetration, bringing antifungal treatments to a broader audience and boosting overall sales for pharmaceutical and personal care brands.
- Rising Health Expenditure:
Global increases in healthcare spending have a direct influence on the accessibility of treatments for onychomycosis, driving onychomycosis treatment demand for antifungal medications. As governments and private sectors allocate more resources to health, individuals benefit from improved medical infrastructure and wider access to effective treatments. Additionally, higher disposable incomes allow consumers to allocate more funds toward personal health needs, including antifungal treatments that may not always be covered by insurance. With more people able to afford premium healthcare products, the market sees an uptick in demand for prescription and over-the-counter options, particularly as onychomycosis awareness grows. This trend is especially prominent in developed countries, where health and wellness are seen as priorities and preventive care is widely promoted. The ability to spend on targeted treatments without financial strain encourages more individuals to address nail fungal infections early on, thus stimulating growth within the antifungal market. As healthcare spending continues to rise, it will likely sustain and expand the market’s reach globally.
Request Sample For PDF Report: https://www.imarcgroup.com/onychomycosis-treatment-market/requestsample
Report Segmentation:
The report has segmented the market into the following categories:
Breakup by Disease Type:
- Distal Subungual Onychomycosis
- Proximal Subungual Onychomycosis
- White Superficial Onychomycosis
- Candidal Onychomycosis
- Others
Distal subungual onychomycosis represents the largest segment as distal subungual onychomycosis is the most prevalent form of nail fungus, contributing significantly to overall cases and driving demand for targeted treatment options.
Breakup by Treatment Type:
- Laser Therapy
- Photodynamic Therapy
- Drug Treatment
Drug treatment accounts for the largest market share including topical and systemic antifungal therapies, which remain the preferred choice for patients and healthcare providers due to their effectiveness and wide availability.
Breakup by Drug Class:
- Allylamine
- Azole
- Griseofulvin
- Others
Based on the drug class, the market has been categorized into allylamine, azole, griseofulvin, and others.
Breakup by Distribution Channel:
- Hospitals and Clinics
- Online Stores
- Retail Pharmacies
- Others
Retail pharmacies dominate the market growth and serve as the primary point of access for patients seeking over-the-counter and prescription treatments, facilitating convenience and accessibility.
Market Breakup by Region:
- North America (United States, Canada)
- Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, Others)
- Europe (Germany, France, United Kingdom, Italy, Spain, Russia, Others)
- Latin America (Brazil, Mexico, Others)
- Middle East and Africa
North America holds the leading position owing to a large market for onychomycosis treatment driven by the rising prevalence of the skin condition, advanced healthcare infrastructure, and significant investments in dermatological research and development.
Top Onychomycosis Treatment Market Leaders:
- Bausch Health Companies Inc.
- Cipla Limited
- Dr. Reddy’s Laboratories
- Galderma SA
- GlaxoSmithKline PLC
- Kaken Pharmaceutical Co. Ltd.
- Lumenis Ltd.
- Moberg Pharma AB
- Novartis AG
- Pfizer Inc.
- The OTC Lab B.V
If you need specific information that is not currently within the scope of the report, we will provide it to you as a part of the customization.
About Us
IMARC Group is a global management consulting firm that helps the world’s most ambitious changemakers to create a lasting impact. The company provide a comprehensive suite of market entry and expansion services. IMARC offerings include thorough market assessment, feasibility studies, company incorporation assistance, factory setup support, regulatory approvals and licensing navigation, branding, marketing and sales strategies, competitive landscape and benchmarking analyses, pricing and cost research, and procurement research.